在不破坏肠道微生物群的情况下,Equol可以中和B毒素以对抗Clostridioides difficile感染
Yan Guo1, Zhiying Liu1, Jianfeng Wang1
1State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, College of Veterinary Medicine, Jilin University, Changchun, China.
一种天然化合物Equol通过抑制B毒素 (TcdB) 和保存肠道微生物群来对抗Clostridioides difficile感染. 这为C. difficile感染提供了一个有前途的新治疗策略.
科学领域:
- 微生物学 微生物学
- 毒理学 毒理学 毒理学
- 药理学 药理学是指药理学的学科.
背景情况:
- Clostridioides difficile B毒素 (TcdB) 是C. difficile致病性的关键,通过小GTPases的糖化诱导宿主细胞亡.
- 抗生素引起的肠道微生物群的破坏增加了对C. difficile感染 (CDI) 的易感性.
- 目前的CDI治疗方法,如万科米辛,具有局限性,包括微生物群的破坏和高复发率,需要新的治疗方法.
研究的目的:
- 确定针对C. difficile感染 (CDI) 的新型治疗剂.
- 研究天然化合物equol在打击TCdB介导的致病性方面的潜力.
- 在CDI的背景下,评估equol对肠道微生物群和氧化应激的影响.
主要方法:
- 研究了equol与TcdB的直接相互作用以抑制Rac1糖化.
- 评估了equol对胺二二氧化酶1 (IDO1) 和二二氧化酶 (TDO) 的抑制作用.
- 评估了equol的抗氧化特性及其减轻TcdB诱导的细胞死亡和氧化损伤的能力.
主要成果:
- 埃科尔直接抑制Rac1的TcdB介导的糖化,减少TcdB诱导的细胞死亡.
- 埃科尔通过抑制IDO1和TDO来抑制托转化为kynurenine,从而保持肠道微生物群的完整性.
- 埃科尔表现出显著的抗氧化活性,减轻TcdB诱导的氧化损伤和随后的细胞死亡.
结论:
- 埃科尔有效地抑制了C. difficile毒素B病原性的关键机制.
- 埃科尔保持了肠道微生物群平衡,并表现出抗氧化特性,解决了CDI的关键方面.
- 埃克沃尔为治疗C. difficile感染提供了一个有前途的治疗候选药物,具有减少复发的潜力.
更多相关视频
12:58A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
09:12A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
相关概念视频
Prevention of Further Absorption of Poison
Enhanced Elimination of Poison
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Bacterial Toxins
Inhibitors of Bacterial DNA Synthesis
